Core Viewpoint - The Portnoy Law Firm has initiated an investigation into possible securities fraud involving Sprouts Farmers Market, Inc., and may file a class action on behalf of investors [1]. Group 1: Legal Action and Investigation - The Portnoy Law Firm is encouraging investors to contact them to discuss their legal rights and options for pursuing claims to recover losses [2]. - The lawsuit alleges that defendants provided misleading information regarding Sprouts' growth potential for fiscal year 2025, claiming resilience in the customer base against macroeconomic pressures [3]. Group 2: Allegations of Misleading Statements - The lawsuit claims that while defendants expressed confidence in Sprouts' growth, they simultaneously concealed material adverse facts that indicated a potential slowdown in sales growth due to a more cautious consumer [3]. - It is asserted that the positive statements made by the defendants were misleading and did not reflect the true state of Sprouts' growth potential, leading to investor damages when the actual details became known [3].

Core Viewpoint - The Portnoy Law Firm has initiated an investigation into Ultragenyx Pharmaceutical, Inc. for possible securities fraud following the failure of its clinical trials, which has led to a significant drop in the company's stock price [1][3]. Group 1: Company Performance - On December 29, 2025, Ultragenyx announced that its Phase III Orbit and Cosmic studies for setrusumab (UX143) did not meet their primary endpoint of reducing annualized clinical fracture rates compared to placebo and biophosphonates [3]. - Although the studies showed improvements in secondary endpoints related to bone material density, these did not correlate with a statistically significant reduction in fractures [3]. - Following the announcement, Ultragenyx's stock price fell by $14.87 (43.49%) to open at $19.32 per share, marking a new 52-week low, significantly below the previous low of $25.81 [3]. Group 2: Legal Actions - The Portnoy Law Firm is representing investors in pursuing claims related to corporate wrongdoing, and has a history of recovering over $5.5 billion for aggrieved investors [3]. - Investors are encouraged to contact the firm for a complimentary case evaluation and to discuss their legal rights regarding potential claims [2].

Core Viewpoint - The Portnoy Law Firm is advising investors of Comerica, Inc. regarding a class action lawsuit related to the company's proposed acquisition by Fifth Third Bancorp [1]. Group 1: Legal Action - Investors are encouraged to contact the Portnoy Law Firm for legal rights discussions and to join the class action case [2]. - The firm offers complimentary case evaluations to discuss options for recovering losses [2]. Group 2: Allegations Against Comerica - The complaint alleges that Comerica's CEO sought a "friendly white knight" after facing pressure from an activist investor, leading to the approach of Fifth Third Bancorp for acquisition [3]. - It is claimed that Comerica's board has implemented "preclusive deal protections" to prevent superior bids from emerging for the company [3].

Core Viewpoint - The Portnoy Law Firm has initiated an investigation into potential securities fraud involving Soleno Therapeutics, Inc. and may file a class action lawsuit on behalf of investors [1][2]. Company Developments - On March 26, 2025, Soleno Therapeutics announced FDA approval for VYKAT XR (diazoxide choline) extended-release tablets aimed at treating hyperphagia in individuals with Prader-Willi syndrome aged 4 and older [3]. - During a quarterly earnings call on November 4, 2025, Soleno disclosed that the discontinuation rate for VYKAT XR due to adverse effects was approximately 8% by the end of Q3 fiscal 2025 [3]. - CEO Anish Bhatnagar acknowledged a disruption in the launch trajectory of VYKAT XR following a short seller report released in mid-August, which resulted in a decrease in start forms and an increase in discontinuations for non-serious adverse events [3]. - Following these developments, Soleno's share price experienced a decline of over 26% [3].

Core Viewpoint - The Portnoy Law Firm is investigating potential securities fraud claims against CS Disco, Inc. and may file a class action on behalf of investors who suffered losses [1][3]. Group 1: Investigation Details - The investigation is initiated following a class action complaint filed on September 19, 2023, covering the period from July 21, 2021, to August 11, 2022 [3]. - The investigation focuses on whether the board of directors of CS Disco breached their fiduciary duties to the company [3]. Group 2: Allegations of Misrepresentation - The complaint alleges that CS Disco highlighted strong revenue growth from its cloud-based electronic discovery platform but failed to disclose significant headwinds that could impact growth [4]. - It is claimed that the company acknowledged its rapid revenue growth was "usage driven" and potentially volatile, yet did not inform investors of any risks [4]. Group 3: Impact of Financial Results - The truth began to emerge on August 11, 2022, when CS Disco reported second-quarter 2022 financial results that fell short of expectations, revealing a significant slowdown in revenue growth [5]. - Following this news, CS Disco's stock price dropped approximately 53% on August 12, 2022, on heavy trading volume [5].

Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, Aug. 14, 2025 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Performant Healthcare, Inc. (“Performant Healthcare” or “the Company”) (NASDAQ: PHLT) investors that the firm has initiated an investigation into possible securities fraud and may file a class action on behalf of investors. Performant Healthcare investors that lost money on their investment are encouraged to contact Lesley Portnoy, Esq. Investo ...

Core Viewpoint - The Portnoy Law Firm has initiated an investigation into potential securities fraud involving American Woodmark Corporation and may file a class action on behalf of affected investors [1][4]. Group 1: Investigation and Legal Actions - The investigation focuses on whether the American Woodmark Board of Directors breached its fiduciary duties by not conducting a fair process regarding the merger with MasterBrand, Inc. [4] - Investors who have incurred losses are encouraged to contact the Portnoy Law Firm for a complimentary case evaluation and to discuss their legal rights [2][5]. Group 2: Merger Details - American Woodmark will be acquired by MasterBrand, Inc., with shareholders receiving 5.150 shares of MasterBrand common stock for each share of American Woodmark [3]. - Post-merger, MasterBrand and American Woodmark shareholders are expected to own approximately 63% and 37% of the combined company, respectively [3].

Core Viewpoint - Sapiens International Corporation N.V. is under investigation for possible securities fraud following disappointing earnings and lowered guidance, prompting potential class action lawsuits from investors [1][3][4]. Financial Performance - On November 8, 2024, Sapiens International reported third-quarter earnings that significantly missed expectations, leading to a reduction in full-year guidance and a forecast of single-digit revenue growth for 2025 [3]. - The company's stock price fell by $10.35 per share, approximately 26.24%, closing at $29.10 per share after the earnings announcement [4]. Reasons for Underperformance - Management cited delays in deal closings, a greater-than-expected impact from clients transitioning from on-premises solutions to SaaS, and increased competition in North America as key factors for the earnings shortfall [3]. - Analysts raised concerns regarding the company's weak performance in North America, attributing it to the SaaS transition and broader economic uncertainty, which are contributing to longer sales cycles and declining revenue growth [3].

Core Viewpoint - Altimmune, Inc. is facing a class action lawsuit due to allegations of misleading investors regarding the results of its IMPACT Phase 2b MASH trial, which failed to meet expectations [1][3]. Group 1: Class Action Details - The class action represents investors who purchased Altimmune securities between August 10, 2023, and June 25, 2025, with a deadline of October 6, 2025, to file a lead plaintiff motion [1]. - Investors are encouraged to contact the Portnoy Law Firm for a complimentary case evaluation and to discuss their legal rights [2]. Group 2: Allegations and Trial Results - The complaint alleges that Altimmune's executives made overly positive statements while concealing material adverse facts about the trial results [3]. - On June 26, 2025, Altimmune announced that one of the primary endpoints in the trial did not achieve statistical significance, attributed to a higher-than-expected placebo response [4]. - Following the announcement, Altimmune's stock price plummeted from $7.71 per share on June 25, 2025, to $3.61 per share on June 26, 2025, marking a significant single-day decline of 53.2% [5].

Core Viewpoint - Insperity, Inc. is under investigation for possible securities fraud following disappointing financial results, which has led to a significant decline in its stock price [1][3][4]. Financial Performance - Insperity reported adjusted earnings per share of $0.26 for Q2 2025, which was a 70% decline compared to the same period in the previous year [3]. - The company attributed the poor performance to higher-than-expected benefits costs, including increased pharmacy expenses and a rise in large insurance claims [3]. - Following the earnings announcement, Insperity's stock price fell by $14.51, or approximately 24.35%, closing at $45.07 per share on August 1, 2025 [4]. Legal Actions - The Portnoy Law Firm has initiated an investigation into Insperity and may file a class action on behalf of investors who suffered losses [1]. - Investors are encouraged to contact the law firm for a complimentary case evaluation and to discuss their legal rights [2].